Clinical Trial Update: A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase IIa trial evaluating sotatercept for bone mass and turnover in patients with multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Rebecca Silbermann | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN